IL3RA and myelodysplastic syndrome: Based on our knowledge of currently approved therapeutic agents for the treatment of high-risk myelodysplastic syndrome (MDS) and AML, we investigated the impact of the DNA methyltransferase inhibitor, AZA, on CD123 expression16,26.